This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Could Be Less Than A Year Away From Profitability
Express News | ACADIA Pharmaceuticals Inc : BMO Initiates Coverage With Outperform Rating; Target Price $31
ACADIA Pharmaceuticals Initiated at Outperform by BMO Capital
BMO Capital Initiates Coverage On ACADIA Pharmaceuticals With Outperform Rating, Announces Price Target of $31
BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $31
BMO Capital analyst Evan Seigerman initiates coverage on $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and sets the target price at $31.According to TipRanks data, the analyst has a success rat
RBC Capital Reiterates Outperform on ACADIA Pharmaceuticals, Maintains $29 Price Target
ACADIA Pharmaceuticals Analyst Ratings
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $29
RBC Capital analyst Gregory Renza maintains $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 44.
Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting
ACADIA Pharmaceuticals Holds Successful 2024 Annual Meeting
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will Probably Find It Hard To See A Huge Raise This Year
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Integer Holdings (ITGR) and ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities
ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag